The RA-MAP Consortium: a working model for academia–industry collaboration

Abstract

Collaboration can be challenging; nevertheless, the emerging successes of large, multi-partner, multi-national cooperatives and research networks in the biomedical sector have sustained the appetite of academics and industry partners for developing and fostering new research consortia. This model has percolated down to national funding agencies across the globe, leading to funding for projects that aim to realise the true potential of genomic medicine in the 21st century and to reap the rewards of ‘big data’. In this Perspectives article, the experiences of the RA-MAP consortium, a group of more than 140 individuals affiliated with 21 academic and industry organizations that are focused on making genomic medicine in rheumatoid arthritis a reality are described. The challenges of multi-partner collaboration in the UK are highlighted and wide-ranging solutions are offered that might benefit large research consortia around the world.

Knowledge transfer for frugal innovation: where do entrepreneurial universities stand?

“…It implies including social partners, by giving them a voice on the university board/committees, or at least to introduce the stakeholders' vision as part of the university strategies (Benneworth and Jongbloed, 2010;Natalicchio et al, 2018). Recent research suggests that a more robust engagement of stakeholders from civil society democratizes the decision-making process; results in closer alignment between scientific priorities and social needs; accelerates the diffusion of research outputs; and enhances trust and transparency (Cope et al, 2018;Olsen et al, 2016;Willyard et al, 2018).…”

Comparing biologicals and small molecule drug therapies for chronic respiratory diseases: An EAACI Taskforce on Immunopharmacology position paper

“…Nevertheless, long‐term sustainability of treatment with biologicals remains a concern while several new, highly promising targeted therapies, approached by both biologicals and SMDs strategies, disappointingly failed to complete drug development phases, generally through lack of patient stratification and/or absence of an appropriate predictive biomarker. Despite these setbacks, many strides have been undertaken to shorten the critical period between preclinical research and approval of a new drug, the so‐called Valley of Death, through new strategies for research and development and increasing collaboration between academia and industry, from biomarker identification to integrated disease approaches . The requirement for adequate biomarkers and targeted therapies needs to be effectively addressed by both biologicals and SMD strategies in order to deliver “the right drug to the right patient” (Table ).…”

Comprehensive exploratory autoantibody profiling in patients with early rheumatoid arthritis treated with methotrexate or tocilizumab

“…A comprehensive multiplex profiling technique was used to measure baseline serum IgG antibodies against 463 human protein antigens, consisting of well-known and novel antigens identified in high-content profiling studies in rheumatic diseases [20][21][22]. The antigen array content was designed as described [23] to include 45 well-known diagnostic rheumatic disease antigens and proteins based on their potential relevance to pathogenic pathways in autoimmune diseases such as cytokines, cytokine receptors, chemokines, interferons and matrix…”